Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease

Background . Anemia is common in inflammatory bowel disease (IBD). Oral iron is widely used but efficacy can be reduced by poor compliance and insufficient absorption. Intravenous iron is safe and effective in adults but is not well studied in children. Purpose . To assess safety and efficacy of int...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramy Sabe MBBCh (Author), Anant Vatsayan MD (Author), Amr Mahran MD (Author), Ali S. Khalili MD (Author), Sanjay Ahuja MD, MSc (Author), Thomas J. Sferra MD (Author)
Format: Book
Published: SAGE Publishing, 2019-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cdf93c8052fb4099a1af9fc709d8c2c8
042 |a dc 
100 1 0 |a Ramy Sabe MBBCh  |e author 
700 1 0 |a Anant Vatsayan MD  |e author 
700 1 0 |a Amr Mahran MD  |e author 
700 1 0 |a Ali S. Khalili MD  |e author 
700 1 0 |a Sanjay Ahuja MD, MSc  |e author 
700 1 0 |a Thomas J. Sferra MD  |e author 
245 0 0 |a Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in Children and Adolescents With Inflammatory Bowel Disease 
260 |b SAGE Publishing,   |c 2019-08-01T00:00:00Z. 
500 |a 2333-794X 
500 |a 10.1177/2333794X19870981 
520 |a Background . Anemia is common in inflammatory bowel disease (IBD). Oral iron is widely used but efficacy can be reduced by poor compliance and insufficient absorption. Intravenous iron is safe and effective in adults but is not well studied in children. Purpose . To assess safety and efficacy of intravenous iron sucrose (IVIS) in children with IBD. Methods . We reviewed medical records of IBD patients <22 years of age who received IVIS at our institution between 2009 and 2014. Anemia was defined as hemoglobin (Hgb) level below normal for age and gender and iron-deficiency anemia as serum iron studies and red cell mean corpuscular volume below normal ranges. Each IVIS infusion was evaluated for safety. Efficacy was defined as ≥2 g/dL increase in Hgb ≤12 weeks from IVIS initiation. Results . We identified 88 patients (Crohn's disease, n = 52; ulcerative colitis, n = 33; IBD-unclassified, n = 3) who underwent 329 IVIS infusions over 121 courses. No patient developed anaphylaxis. Six patients developed minor adverse reactions. Of the 121 IVIS courses, 80 were included in the efficacy evaluation. There was a significant rise in Hgb (mean 9.1 ±1.4 to 11.9 ± 1.8 g/dL; P < .0001, paired t test). Overall, 58.7% (47/80 courses) resulted in goal Hgb increase. Conclusions . IVIS is safe and effective in treating iron-deficiency anemia in pediatric IBD. There were only minor adverse events, and the observed rise in Hgb was clinically significant, with the majority achieving goal Hgb. 
546 |a EN 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Global Pediatric Health, Vol 6 (2019) 
787 0 |n https://doi.org/10.1177/2333794X19870981 
787 0 |n https://doaj.org/toc/2333-794X 
856 4 1 |u https://doaj.org/article/cdf93c8052fb4099a1af9fc709d8c2c8  |z Connect to this object online.